TueJul 20th, 2021
Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer [...]
MonMay 3rd, 2021
Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform
Lantern Pharma and Actuate Therapeutics Announce Research & Development [...]
ThuApr 29th, 2021
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company’s Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company’s Strategy to Develop the World’s Largest A.I. Platform for Oncology-Focused Drug Development & Rescue
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug [...]
TueMar 23rd, 2021
Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
Lantern Pharma to Present New Data Supporting the Advancement [...]
WedMar 17th, 2021
Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties
Lantern Pharma Announces Filing of Seven Patent Applications Globally [...]
WedMar 10th, 2021
Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights
Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial [...]